365996-06-1

Basic information

• Product Name: tert-butyl 2-bromo-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate
• Synonyms: tert-butyl 2-bromo-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate;5-Boc-2-bromo-6,7-dihydro-4H-thiazolo[5,4-c]pyridine;tert-butyl 2-bromo-6,7-dihydro[1,3]thiazolo[5,4-c]pyridine-5(4H)-carboxylate;tert-butyl 2-broMo-6;2-BroMo-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylicacidtert-butylester;2-Bromo-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine, N-BOC protected;Thiazolo[5,4-c]pyridine-5(4H)-carboxylic acid, 2-broMo-6,7-dihydro-, 1,1-diMethylethyl ester;tert-butyl 2-broMo-4H,5H,6H,7H-[1,3]thiazolo[5,4- c]pyridine-5-carboxylate
• CAS NO: 365996-06-1
• Molecular Formula: C₁₁H₁₅BrN₂O₂S
• Molecular Weight: 319.22
• Product Categories: CHIRAL CHEMICALS;Heterocycle-Pyridine series
• Mol File: 365996-06-1.mol
• Article Data: 19

Chemical Properties

• Melting Point: 42-44 °C(Solv: ethyl ether (60-29-7))
• Boiling Point: 390.946 °C at 760 mmHg
• Flash Point: 190.238 °C
• Appearance: /
• Density: 1.496 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.58
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.23±0.20(Predicted)
• CAS DataBase Reference: tert-butyl 2-bromo-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-bromo-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate(365996-06-1)
• EPA Substance Registry System: tert-butyl 2-bromo-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate(365996-06-1)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN2811
• Hazardous Substances Data: 365996-06-1(Hazardous Substances Data)

Usage

Uses

2-Bromo-5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine is a reagent used for the synthesis of tetrahydrothiazolopyridines, which are potent antagonists for the smoothened (smo) receptor.

InChI:InChI=1/C11H15BrN2O2S/c1-11(2,3)16-10(15)14-5-4-7-8(6-14)17-9(12)13-7/h4-6H2,1-3H3

Upstream product

• 365996-05-0 tert-butyl 2-amino-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 949922-52-5 2-bromo-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine hydrochloride 
• 207691-65-4 N-tert-butoxycarbonyl-4-(tetrahydropyrrole-1-yl)-1,2,3,6-tetrahydropyridine 
• 540-80-7 tert.-butylnitrite 
• 188869-05-8 tert-butyl 3-bromo-4-oxo-piperidine-1-carboxylate 
• 7789-45-9 copper(II)bromide 

Downstream Products

• 365996-07-2 2-bromo-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine 
• 165948-24-3 5-tert-Butoxycarbonyl-4,5,6,7-tetrahydrothiazolo[5,4-c]-pyridine 
• 165948-23-2 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine 
• 1575609-63-0 (2R,3R)-3-(2-(2-methoxypyrimidin-5-yl)-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)-2-(2,4-di-fluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575609-62-9 (2R,3R)-3-(2-(2-methylpyrimidin-5-yl)-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)-2-(2,4-di-fluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575609-59-4 (2R,3R)-3-(2-(2-methoxypyridin-5-yl)-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)-2-(2,4-di-fluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575609-57-2 (2R,3R)-3-(2-(2-fluoropyridin-5-yl)-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575609-55-0 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(pyrimidin-5-yl)-6,7-dihydrothiazolo[5,4-c]piperidine-5(4H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575609-52-7 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(2-cyanopyridin-5-yl)-6,7-dihydrothiazolo[5,4-c]piperidine-5(4H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575609-49-2 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(3-cyanopyridin-5-yl)-6,7-dihydrothiazolo[5,4-c]piperidine-5(4H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575609-48-1 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(3-fluoropyridin-5-yl)-6,7-dihydrothiazolo[5,4-c]piperidine-5(4H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575609-46-9 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(pyridin-3-yl)-6,7-dihydrothiazolo[5,4-c]piperidine-5(4H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575609-43-6 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(pyridin-4-yl)-6,7-dihydrothiazolo[5,4-c]piperidine-5(4H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575609-41-4 (2R,3R)-3-(2-(thiophen-3-yl)-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 

Relevant articles and documents

1-[2-(1-Cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition

A series of chemical optimizations, which was guided by in vitro affinity at histamine H3 receptor (H3R), modulation of lipophilicity, ADME properties and preclinical efficacy resulted in the identification of 1-[2-(1-cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one (45 e) as a potent and selective (Ki=4.0 nM) H3R inverse agonist. Dipsogenia induced by (R)-α-methylhistamine was dose dependently antagonized by 45 e, confirming its functional antagonism at H3R. It is devoid of hERG and phospholipidosis issues. Compound 45 e has adequate oral exposures and favorable half-life in both rats and dogs. It has demonstrated high receptor occupancy (ED80=0.22 mg/kg) and robust efficacy in object recognition task and, dose dependently increased acetylcholine levels in brain. The sub-therapeutic doses of 45 e in combination with donepezil significantly increased acetylcholine levels. The potent affinity, selectivity, in vivo efficacy and drug like properties together with safety, warrant for further development of this molecule for potential treatment of cognitive disorders associated with Alzheimer's disease.

BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS

Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

Substituted tetrahydroisoquinoline compound and application

The invention discloses a substituted tetrahydroisoquinoline compound and application. The compound has a structure as shown in a general formula I in the specification; and in the general formula I, substituents are defined in the specification. The comp